Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02012608 · ClinicalTrials.gov registry record · Phase 2
Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02012608 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 14 participants.
The verdict
NCT02012608, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.
Interventions
- DRUG Placebo
- DRUG Glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02012608
The ClinicalTrials.gov registry entry for NCT02012608 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02012608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02012608 about?
NCT02012608 is a clinical study titled "Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy". This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.
What is the current status of trial NCT02012608?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2014-06. Estimated completion is 2019-04.
What interventions are being tested in trial NCT02012608?
The interventions under investigation include: Placebo (DRUG), Glutamine (DRUG).
Who is sponsoring clinical trial NCT02012608?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.